


I hereby certify under 37 CFR § 1.8 that this document and referenced attachments are being deposited with the United States Postal Service having sufficient postage as First Class Mail in an envelope addressed to:  
Mail Stop PCT, Commissioner for Patents,  
P.O. Box 1450, Alexandria, VA 22313-1450  
on 6<sup>th</sup> January 2010  
Printed: Matthew R. Kaser  
Signed: 

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re U.S. National Phase Application of:  
BARBAS, Carlos F. and CHUNG, Junho**

**Title: INTEGRIN  $\alpha_{II}B\beta_3$  SPECIFIC ANTIBODIES AND PEPTIDES**

<b>U.S. Application No.</b>	<b>10/581,431</b>
International application number:	PCT/US04/040381
International Filing Date:	3 December 2004
Priority application number:	US 60/526,859
Priority date:	3 December 2003

---

To:  
Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Enclosed:

- Return receipt postcard
- Transmittal Form
- Response to Notification of Defective Response
- Statement of Submission of Sequence Listing in CRF
- Sequence Listing, paper copy (21 pages)
- Sequence Listing, CFR, CD-ROM x 2
- Copy of USPTO Decision of Petition for Waiver of Examination Fees
- Copy of Notification of Defective Response mailed 12/23/2009

Respectfully submitted,



Matthew Kaser, D.Phil.  
Reg. No. 44,817

Bell & Associates  
58 West Portal Avenue, # 121  
San Francisco, California 94127  
Tel: (510) 537-2040  
Fax: (415) 276-6040  
mkaser@bell-iplaw.com

I hereby certify under 37 CFR § 1.8 that this document and referenced attachments are being deposited with the United States Postal Service having sufficient postage as First Class Mail in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450  
On: 6 January 2010

Signed:   
Printed: Matthew Kaser

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Mail Stop PCT  
Commissioner for Patents  
PO Box 1450  
Alexandria  
VA 22313-1450

**US Application No.: 10/581,431**  
International Application No.: PCT/US04/40381  
International Filing Date: 3 December, 2004  
Title: Integrin  $\alpha_{IIb}\beta_3$  Specific Antibodies and Peptides  
Inventors: BARBAS, Carlos F. and CHUNG, Junho  
Attorney Docket No. TSRI 1019.1 US

**Response to Notification of Defective Response**

Sir,

This is a Response to the Notification of Defective Response, mailed December 23, 2009. This response is timely filed. A copy of the Notification of Defective Response is enclosed.


The Notification states that Applicants Response (filed February 8, 2008) to the Notification to Comply with Requirements, mailed February 6, 2007 have not been completed with regard to the correct format of the previously filed "Sequenced Listing". Applicants herewith submit a substitute Sequence Listing both in paper and electronic format (CRF).

The Notification also states that the Application Examination Fee has not been paid and that Applicants must submit \$220 to complete the Examination Fee for a non-small entity.

Regarding requirement for payment of the Examination Fee, we enclose a copy of the Decision from the Office of PCT Legal Administration, dated 29 October 2007, in response to Applicants' Petition for Waiver of Examination Fees. The Decision indicates that Applicants' Petition was **GRANTED** and that the appropriate examination fee for the present application is **\$0** (page 2, last line and page 3 first line). Applicants respectfully request clarification regarding this paradox.

Applicants believe that this response does not require payment of a fee. However, if the Commissioner finds any additional charges or fees must be paid in connection with this communication, they may be paid out of **Bell & Associates Deposit Account No. 50-3194**. The Commissioner is also authorized to credit any overpayment.

Respectfully submitted,

  
Matthew Kaser, D.Phil.  
44,817  
Bell & Associates  
58 West Portal Avenue # 121  
San Francisco CA 94127  
Phone: (510) 537-2040  
Fax: (415) 276-6040  
mkaser@bell-iplaw.com



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/581,431	Carlos F Barbas	

39843  
BELL & ASSOCIATES  
58 West Portal Avenue No. 121  
SAN FRANCISCO, CA 94127

INTERNATIONAL APPLICATION NO.	
PCT/US04/40381	
I.A. FILING DATE	PRIORITY DATE
12/03/2004	12/03/2003

**CONFIRMATION NO: 5101**  
**371 FORMALITIES LETTER**



Date Mailed: 12/23/2009

## NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated Office (37 CFR 1.494):

- Priority Document
- Copy of the International Application filed on 06/02/2006
- Copy of the International Search Report filed on 06/02/2006
- Copy of IPE Report filed on 06/02/2006
- Preliminary Amendments filed on 06/02/2006
- Biochemical Sequence Diskette filed on 06/12/2009
- Oath or Declaration filed on 02/08/2008
- Biochemical Sequence Listing filed on 06/04/2007
- Request for Immediate Examination filed on 06/02/2006
- U.S. Basic National Fees filed on 06/02/2006
- Priority Documents filed on 06/02/2006
- Power of Attorney filed on 06/02/2006

Applicant's response filed 06/12/2009 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 02/06/2007 have not been completed.

The applicant needs to satisfy supplemental fees problems indicated below.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

### SUMMARY OF FEES DUE:

Total additional fees required for this application is **\$220** for a Large Entity:

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Refer to attachment or PAIR document dated Seq. listing can not be entered do to errors.

**Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).**

- The application examination fee has not been paid. Applicant must submit \$220 to complete the examination fee for a non-small entity. Note a surcharge will be required if submitted later than commencement of the national stage (37 CFR 1.492(h)) and the basic national fee was not paid before July 1, 2005.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

**For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:**

- For Rules Interpretation, call (571) 272-0951
- For PatentIn Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for PatentIn Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.

<https://portal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

**If you are not using EFS-Web to submit your reply, you must include a copy of this notice.**

WENDY A TRICE

---

Telephone: (703) 756-1419